High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
复制标题
高剂量 VP 16-213 (NSC 141540) 用于治疗既往接受过治疗的急性白血病患者。
DOI：
--
复制
发表时间：
1980
期刊：
影响因子：
--
通讯作者：
Joseph Aisner
中科院分区：
文献类型：
--
作者：
Van Echo Da;P. H. Wiernik;Joseph Aisner
13 名复发性急性白血病患者、12 名患有急性非淋巴细胞白血病的成人和一名患有急性淋巴细胞白血病的儿童接受 VP 16-213（一种表鬼臼毒素类似物）治疗，剂量为 200-300 mg/m2/天 X5，静脉输注 2 小时。只有四名患者出现骨髓再生障碍，三名患者出现白血病细胞再生。第四位患者获得了 4 周的部分缓解。毒性包括骨髓抑制（白细胞最低点500/微升）、恶心和呕吐（70%的疗程）、粘膜炎（23%）、食管炎（12%）（导致一名患者死亡）、低血压（12%）和短暂的肝功能异常（12%）。结论是，增加本研究中使用的VP 16-213的剂量并没有增加VP 16-213治疗复发性白血病的治疗活性，但确实增加了毒性风险。
Thirteen patients with relapsed acute leukemia, 12 adults with acute nonlymphocytic leukemia, and one child with acute lymphoblastic leukemia were treated with VP 16-213, an epipodophyllotoxin analog, at a dose of 200-300 mg/m2/day X5 as a 2-hour intravenous infusion. Only four patients achieved bone marrow aplasia and three regenerated with leukemic cells. The fourth patient achieved a partial remission for 4 weeks. Toxicities included myelosuppression (WBC nadir 500/microliter), nausea and vomiting (70% of courses), mucositis (23%), esophagitis (12%), which contributed to death in one patient, hypotension (12%), and transient liver function abnormalities (12%). It is concluded that increasing the dose of VP 16-213 as employed in this study did not increase the therapeutic activity of VP 16-213 for the treatment of relapsed leukemia but did increase the risk of toxicity.